| 30.16 0.86 (2.94%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 35.23 |
1-year : | 41.15 |
| Resists | First : | 30.17 |
Second : | 35.23 |
| Pivot price | 28.79 |
|||
| Supports | First : | 26.45 |
Second : | 24.15 |
| MAs | MA(5) : | 29.2 |
MA(20) : | 27.8 |
| MA(100) : | 27.13 |
MA(250) : | 32.56  |
|
| MACD | MACD : | 0.8 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 89.1 |
D(3) : | 82.8 |
| RSI | RSI(14): 67.3 |
|||
| 52-week | High : | 42.45 | Low : | 24.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ GLPG ] has closed below upper band by 17.4%. Bollinger Bands are 25.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 30.19 - 30.28 | 30.28 - 30.38 |
| Low: | 29.18 - 29.29 | 29.29 - 29.41 |
| Close: | 29.96 - 30.13 | 30.13 - 30.32 |
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Wed, 11 Sep 2024
Research Analysts Offer Predictions for Galapagos NV's Q3 2024 Earnings (NASDAQ:GLPG) - MarketBeat
Tue, 10 Sep 2024
Galapagos NV (NASDAQ:GLPG) Receives $31.00 Consensus PT from Brokerages - MarketBeat
Mon, 26 Aug 2024
Major Investor Says Galapagos Is 'Undervalued,' Plans To Push On Company's 'Performance' And 'Strategic Opportunities' - Benzinga
Fri, 23 Aug 2024
Galapagos stock gains after FDA nod for trial (NASDAQ:GLPG) - Seeking Alpha
Fri, 23 Aug 2024
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance
Thu, 01 Aug 2024
BridGene Biosciences Expands Strategic Collaboration with Galapagos to Develop Selective Oral SMARCA2 PROTAC in Precision Oncology - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 66 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 32.2 (%) |
| Shares Short | 1,460 (K) |
| Shares Short P.Month | 1,480 (K) |
| EPS | 0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 44.15 |
| Profit Margin | 108.1 % |
| Operating Margin | -49.1 % |
| Return on Assets (ttm) | -1.8 % |
| Return on Equity (ttm) | 1.1 % |
| Qtrly Rev. Growth | 29.7 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 3.96 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 74.8 % |
| Operating Cash Flow | -375 (M) |
| Levered Free Cash Flow | -293 (M) |
| PE Ratio | 56.9 |
| PEG Ratio | 2.4 |
| Price to Book value | 0.68 |
| Price to Sales | 7.6 |
| Price to Cash Flow | -5.31 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|